The essence of cell immunotherapy is to stimulate a patient’s own anti-cancer immune cells, such as T cells. As a result, the patient's immune response to tumor burdens can be boosted and tumor proliferation can be significantly inhibited. Other benefits may include mild side effects and low recurrence rates. Therefore, the therapy is a better choice for elderly patients who usually have poor immunity and can’t handle the toxic side effects resulting from traditional chemotherapy. This therapy may work for all cancer stages. Not only can early stage cancer patients benefit from the treatment, patients with advanced cancers may also achieve partial or complete remission after receiving the treatment. The therapy is currently used to treat prostate cancer, malignant melanoma, lung cancer, nasopharyngeal cancer, liver cancer, gastric cancer and other malignant tumors.
XLifeSc is committed to developing genetically modified T cells with enhanced affinity and specificity for tumor antigens to achieve better efficacy without severe side effects. The technology platform encompasses target identification, T cell cloning, TCR optimization, T cell modification and T cell amplification.
